Quest Diagnostics Incorporated Company Profile (NYSE:DGX)

About Quest Diagnostics Incorporated (NYSE:DGX)

Quest Diagnostics Incorporated logoQuest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Healthcare Facilities & Services
  • Sub-Industry: Health Care Services
  • Symbol: NYSE:DGX
  • CUSIP: 74834L10
  • Web:
  • Market Cap: $12.57386 billion
  • Outstanding Shares: 136,405,000
Average Prices:
  • 50 Day Moving Avg: $98.89
  • 200 Day Moving Avg: $104.64
  • 52 Week Range: $79.12 - $112.97
  • Trailing P/E Ratio: 18.55
  • Foreward P/E Ratio: 15.76
  • P/E Growth: 2.18
Sales & Book Value:
  • Annual Revenue: $7.59 billion
  • Price / Sales: 1.65
  • Book Value: $34.54 per share
  • Price / Book: 2.67
  • Annual Dividend: $1.80
  • Dividend Yield: 2.0%
  • EBITDA: $1.44 billion
  • Net Margins: 9.28%
  • Return on Equity: 15.66%
  • Return on Assets: 7.24%
  • Debt-to-Equity Ratio: 0.79%
  • Current Ratio: 1.64%
  • Quick Ratio: 1.55%
  • Average Volume: 1.07 million shs.
  • Beta: 0.65
  • Short Ratio: 5.9

Frequently Asked Questions for Quest Diagnostics Incorporated (NYSE:DGX)

What is Quest Diagnostics Incorporated's stock symbol?

Quest Diagnostics Incorporated trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics Incorporated pay dividends? What is the dividend yield for Quest Diagnostics Incorporated?

Quest Diagnostics Incorporated declared a quarterly dividend on Friday, August 18th. Shareholders of record on Tuesday, October 3rd will be given a dividend of $0.45 per share on Wednesday, October 18th. This represents a $1.80 annualized dividend and a yield of 1.96%. The ex-dividend date is Monday, October 2nd. View Quest Diagnostics Incorporated's Dividend History.

How will Quest Diagnostics Incorporated's stock buyback program work?

Quest Diagnostics Incorporated declared that its Board of Directors has approved a share buyback program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 7.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board believes its stock is undervalued.

How were Quest Diagnostics Incorporated's earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) posted its quarterly earnings results on Tuesday, July, 25th. The company reported $1.55 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.13. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics Incorporated had a net margin of 9.28% and a return on equity of 15.66%. The business's revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.34 earnings per share. View Quest Diagnostics Incorporated's Earnings History.

When will Quest Diagnostics Incorporated make its next earnings announcement?

Quest Diagnostics Incorporated is scheduled to release their next quarterly earnings announcement on Thursday, October, 19th 2017. View Earnings Estimates for Quest Diagnostics Incorporated.

What guidance has Quest Diagnostics Incorporated issued on next quarter's earnings?

Quest Diagnostics Incorporated updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $5.62-5.72 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.57. The company issued revenue guidance of $7.69-7.74 billion, compared to the consensus revenue estimate of $7.69 billion.

Where is Quest Diagnostics Incorporated's stock going? Where will Quest Diagnostics Incorporated's stock price be in 2017?

17 equities research analysts have issued twelve-month price objectives for Quest Diagnostics Incorporated's stock. Their predictions range from $88.00 to $122.00. On average, they expect Quest Diagnostics Incorporated's stock price to reach $106.79 in the next twelve months. View Analyst Ratings for Quest Diagnostics Incorporated.

What are analysts saying about Quest Diagnostics Incorporated stock?

Here are some recent quotes from research analysts about Quest Diagnostics Incorporated stock:

  • 1. According to Zacks Investment Research, "Over the last year, Quest Diagnostics has been trading above the broader industry. The company’s earnings in the last reported quarter exceeded the estimates, while revenues lagged the same. On a positive note, it has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. It is currently refocusing on core diagnostic information services business and disciplined capital deployment. Finally, the raised 2017 guidance indicates about this bullish trend to continue ahead. In addition, alliance with hospitals and integrated delivery networks are the other growth drivers. Particularly, the company is positive about its acquisition of PeaceHealth in the Pacific Northwest which is expected to bolster growth in the rest 2017. However, we are concerned about tough organic volume scenario. Tough competitive landscape and reimbursement headwinds are other concerns." (10/3/2017)
  • 2. Jefferies Group LLC analysts commented, "We are maintaining our Hold on DGX given our view that significant multiple expansion is unlikely from its current 10-year high P/E. That said, we do not expect its valuation to crack either given the company's stable fundamentals, the emerging opportunity with hospital labs, consistent dividend & buybacks, potential upside from US tax reform, and the composition of its shareholder base." (1/27/2017)

Who are some of Quest Diagnostics Incorporated's key competitors?

Who are Quest Diagnostics Incorporated's key executives?

Quest Diagnostics Incorporated's management team includes the folowing people:

  • Stephen H. Rusckowski, Chairman of the Board, President, Chief Executive Officer
  • Mark J. Guinan, Chief Financial Officer, Executive Vice President
  • James E. Davis, Executive Vice President, General Diagnostics
  • Michael E. Prevoznik, Senior Vice President, General Counsel
  • Jon Roger Cohen M.D., Senior Vice President, Group Executive - Diagnostic Solutions
  • Everett V. Cunningham, Senior Vice President - Commercial
  • Catherine T. Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing
  • Carrie Eglinton Manner, Senior Vice President - Advanced Diagnostics
  • Daniel C. Stanzione Ph.D., Lead Independent Director
  • Jenne K. Britell Ph.D., Independent Director

How do I buy Quest Diagnostics Incorporated stock?

Shares of Quest Diagnostics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics Incorporated's stock price today?

One share of Quest Diagnostics Incorporated stock can currently be purchased for approximately $92.05.

MarketBeat Community Rating for Quest Diagnostics Incorporated (NYSE DGX)
Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  531 (Vote Underperform)
Total Votes:  793
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Quest Diagnostics Incorporated (NYSE:DGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 10 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $106.79 (16.02% upside)
Consensus Price Target History for Quest Diagnostics Incorporated (NYSE:DGX)
Price Target History for Quest Diagnostics Incorporated (NYSE:DGX)
Analysts' Ratings History for Quest Diagnostics Incorporated (NYSE:DGX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Craig HallumReiterated RatingHold$110.00 -> $100.00N/AView Rating Details
10/15/2017SunTrust Banks, Inc.Set Price TargetHold$105.00N/AView Rating Details
10/12/2017Wells Fargo & CompanyInitiated CoverageUnderperform -> Market Perform$88.00N/AView Rating Details
10/10/2017Goldman Sachs Group, Inc. (The)DowngradeConviction-Buy -> Buy$121.00 -> $113.00N/AView Rating Details
9/28/2017Credit Suisse GroupLower Price TargetNeutral$110.00 -> $99.00LowView Rating Details
9/25/2017Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformHighView Rating Details
9/13/2017Canaccord GenuityReiterated RatingBuy$118.00MediumView Rating Details
8/10/2017Morgan StanleyBoost Price TargetUnderweight$87.00 -> $92.00LowView Rating Details
7/25/2017Bank of America CorporationUpgradeNeutral -> Buy$111.00 -> $118.00MediumView Rating Details
7/25/2017Piper Jaffray CompaniesBoost Price TargetNeutral$107.00HighView Rating Details
7/19/2017Barclays PLCReiterated RatingHold$110.00LowView Rating Details
6/28/2017Evercore ISIReiterated RatingIn-Line$104.50LowView Rating Details
6/5/2017MizuhoBoost Price TargetBuy -> Buy$115.00 -> $122.00LowView Rating Details
5/12/2017ArgusInitiated CoverageHold -> Hold$102.00LowView Rating Details
4/23/2017Deutsche Bank AGReiterated RatingBuy$108.00 -> $115.00LowView Rating Details
4/12/2017FBR & CoBoost Price TargetOutperform$103.00 -> $110.00LowView Rating Details
3/16/2017Jefferies Group LLCReiterated RatingHold$96.00MediumView Rating Details
9/9/2016Citigroup Inc.Initiated CoverageNeutral$86.00N/AView Rating Details
6/24/2016Jyske BankDowngradeNeutral -> SellN/AView Rating Details
5/22/2016KeyCorpReiterated RatingHoldN/AView Rating Details
5/16/2016Robert W. BairdReiterated RatingHoldN/AView Rating Details
4/22/2016Royal Bank Of CanadaBoost Price TargetSector Perform$70.00 -> $76.00N/AView Rating Details
1/29/2016William BlairReiterated RatingHoldN/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Quest Diagnostics Incorporated (NYSE:DGX)
Earnings by Quarter for Quest Diagnostics Incorporated (NYSE:DGX)
Earnings History by Quarter for Quest Diagnostics Incorporated (NYSE DGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/19/2017Q3 2017$1.35N/AView Earnings Details
7/25/2017Q2 2017$1.42$1.55$1.94 billion$1.94 billionViewN/AView Earnings Details
4/20/2017Q1 2017$1.18$1.33$1.87 billion$1.90 billionViewN/AView Earnings Details
1/26/2017Q416$1.27$1.31$1.86 billion$1.86 billionViewListenView Earnings Details
10/20/2016Q316$1.35$1.37$1.53 billion$1.89 billionViewListenView Earnings Details
7/21/2016Q216$1.32$1.34$1.91 billion$1.91 billionViewListenView Earnings Details
4/21/2016Q116$1.12$1.12$1.82 billion$1.86 billionViewListenView Earnings Details
1/28/2016Q415$1.19$1.19$1.85 billion$1.85 billionViewListenView Earnings Details
10/22/2015Q315$1.26$1.28$1.89 billion$1.88 billionViewListenView Earnings Details
7/23/2015Q215$1.23$1.25$1.93 billion$1.93 billionViewListenView Earnings Details
4/23/2015Q115$1.04$1.05$1.85 billion$1.84 billionViewListenView Earnings Details
1/29/2015Q414$1.05$1.08$1.85 billion$1.90 billionViewListenView Earnings Details
10/23/2014Q314$1.08$1.10$1.87 billion$1.90 billionViewListenView Earnings Details
7/24/2014Q214$1.06$1.08$1.88 billion$1.90 billionViewN/AView Earnings Details
4/24/2014Q114$0.89$0.84$1.75 billion$1.75 billionViewListenView Earnings Details
1/30/2014Q413$0.93$0.97$1.74 billion$1.76 billionViewListenView Earnings Details
10/17/2013Q313$1.20$1.02$1.84 billion$1.79 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.10$1.06$1.84 billion$1.82 billionViewListenView Earnings Details
4/17/2013Q1 2013$1.03$0.89$1.86 billion$1.80 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.02$1.01$1.83 billion$1.77 billionViewListenView Earnings Details
10/17/2012$1.18$1.18ViewN/AView Earnings Details
7/19/2012$1.17$1.17ViewN/AView Earnings Details
4/18/2012$1.01$1.07ViewN/AView Earnings Details
1/24/2012$1.06$1.23ViewN/AView Earnings Details
10/25/2011$1.11$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$1.01$1.00ViewN/AView Earnings Details
1/25/2011$0.91$0.98ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Quest Diagnostics Incorporated (NYSE:DGX)
2017 EPS Consensus Estimate: $5.37
2018 EPS Consensus Estimate: $5.92
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$1.16$1.18$1.17
Q2 20175$1.39$1.43$1.42
Q3 20175$1.34$1.44$1.40
Q4 20175$1.36$1.45$1.39
Q1 20183$1.30$1.38$1.35
Q2 20183$1.55$1.56$1.55
Q3 20183$1.53$1.56$1.54
Q4 20183$1.46$1.51$1.48
Q1 20191$1.52$1.52$1.52
Q2 20191$1.67$1.67$1.67
(Data provided by Zacks Investment Research)


Current Dividend Information for Quest Diagnostics Incorporated (NYSE:DGX)
Most Recent Dividend:10/18/2017
Annual Dividend:$1.80
Dividend Yield:1.96%
Dividend Growth:9.60% (3 Year Average)
Payout Ratio:36.29% (Trailing 12 Months of Earnings)
31.97% (Based on This Year's Estimates)
30.82% (Based on Next Year's Estimates)
Track Record:5 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Quest Diagnostics Incorporated (NYSE:DGX)

Dividend History by Quarter for Quest Diagnostics Incorporated (NYSE DGX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Quest Diagnostics Incorporated (NYSE:DGX)
Insider Ownership Percentage: 1.75%
Institutional Ownership Percentage: 86.99%
Insider Trades by Quarter for Quest Diagnostics Incorporated (NYSE:DGX)
Institutional Ownership by Quarter for Quest Diagnostics Incorporated (NYSE:DGX)
Insider Trades by Quarter for Quest Diagnostics Incorporated (NYSE:DGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2017Stephen H RusckowskiChairmanSell59,235$108.16$6,406,857.60View SEC Filing  
9/11/2017Daniel StanzioneDirectorSell40,900$108.07$4,420,063.00View SEC Filing  
9/11/2017Stephen H RusckowskiCEOSell53,933$108.16$5,833,393.28View SEC Filing  
9/5/2017Daniel StanzioneDirectorSell3,803$108.01$410,762.03View SEC Filing  
9/5/2017Stephen H RusckowskiChairmanSell2,525$108.03$272,775.75View SEC Filing  
8/4/2017Jeffrey M LeidenDirectorSell296$106.66$31,571.36View SEC Filing  
7/27/2017Jeffrey M LeidenDirectorSell1,304$108.73$141,783.92View SEC Filing  
6/19/2017Catherine T DohertySVPSell59,762$107.55$6,427,403.10View SEC Filing  
4/24/2017Jenne K BritellDirectorSell6,111$104.03$635,727.33View SEC Filing  
4/20/2017Michael E PrevoznikSVPSell29,513$100.00$2,951,300.00View SEC Filing  
3/16/2017Michael E PrevoznikSVPSell13,987$100.00$1,398,700.00View SEC Filing  
3/3/2017Catherine T DohertySVPSell7,162$98.28$703,881.36View SEC Filing  
2/27/2017Michael E PrevoznikSVPSell440$97.39$42,851.60View SEC Filing  
1/30/2017Catherine T DohertySVPSell80,000$90.58$7,246,400.00View SEC Filing  
8/19/2016Jenne K BritellDirectorSell4,000$84.76$339,040.00View SEC Filing  
8/10/2016Jenne K BritellDirectorSell4,000$85.20$340,800.00View SEC Filing  
8/3/2016Jeffrey M LeidenDirectorSell6,345$85.62$543,258.90View SEC Filing  
7/25/2016John B. ZieglerDirectorSell1,000$84.36$84,360.00View SEC Filing  
5/27/2016Catherine T DohertySVPSell47,334$77.27$3,657,498.18View SEC Filing  
5/12/2016Jenne K BritellDirectorSell8,000$75.68$605,440.00View SEC Filing  
5/9/2016Everett CunninghamSVPSell56,312$76.26$4,294,353.12View SEC Filing  
5/6/2016Everett CunninghamSVPSell50,447$76.00$3,833,972.00View SEC Filing  
4/25/2016Catherine T DohertySVPSell29,550$74.45$2,199,997.50View SEC Filing  
3/3/2015Michael E PrevoznikSVPSell3,261$71.16$232,052.76View SEC Filing  
2/11/2015Daniel StanzioneDirectorSell8,000$70.97$567,760.00View SEC Filing  
2/4/2015Gail R WilenskyDirectorSell8,000$72.34$578,720.00View SEC Filing  
2/3/2015John B ZieglerDirectorSell8,000$71.88$575,040.00View SEC Filing  
2/2/2015Thomas F BongiornoVPSell3,000$71.50$214,500.00View SEC Filing  
11/17/2014Jon R CohenSVPSell160,029$63.13$10,102,630.77View SEC Filing  
8/8/2014Catherine T DohertySVPSell25,000$60.12$1,503,000.00View SEC Filing  
8/4/2014Michael E PrevoznikSVPSell14,377$61.01$877,140.77View SEC Filing  
7/30/2014Jenne K BritellDirectorSell8,000$62.37$498,960.00View SEC Filing  
7/30/2014Michael E PrevoznikSVPSell16,384$62.51$1,024,163.84View SEC Filing  
7/29/2014John C Md BaldwinDirectorSell8,000$62.31$498,480.00View SEC Filing  
7/28/2014Thomas F BongiornoVPSell4,000$61.72$246,880.00View SEC Filing  
7/25/2014John B ZieglerDirectorSell8,000$61.90$495,200.00View SEC Filing  
5/22/2014John ZieglerDirectorSell2,973$57.65$171,393.45View SEC Filing  
5/7/2014Gary PfeifferDirectorSell10,000$55.95$559,500.00View SEC Filing  
5/5/2014Mark GuinanCFOBuy4,000$55.51$222,040.00View SEC Filing  
2/27/2014Jenne BritellDirectorSell10,000$52.74$527,400.00View SEC Filing  
2/19/2014Michael PrevoznikSVPSell2,860$52.26$149,463.60View SEC Filing  
2/18/2014Gail WilenskyDirectorSell30,000$52.93$1,587,900.00View SEC Filing  
2/6/2014Timothy MainDirectorBuy5,000$50.71$253,550.00View SEC Filing  
11/5/2013Thomas F BongiornoVPSell16,667$62.49$1,041,520.83View SEC Filing  
10/29/2013Thomas F BongiornoVPSell6,000$59.00$354,000.00View SEC Filing  
10/25/2013Gary M PfeifferDirectorSell2,000$58.10$116,200.00View SEC Filing  
9/17/2013Catherine DohertySVPSell43,334$62.00$2,686,708.00View SEC Filing  
8/14/2013Catherine DohertySVPSell33,000$59.85$1,975,050.00View SEC Filing  
8/12/2013John ZieglerDirectorSell1,953$59.45$116,105.85View SEC Filing  
8/8/2013Thomas BongiornoVPSell10,864$59.33$644,561.12View SEC Filing  
7/23/2013Jenne K BritellDirectorSell4,200$58.99$247,758.00View SEC Filing  
6/18/2013Michael E PrevoznikSVPSell126,667$62.64$7,934,420.88View SEC Filing  
5/22/2013John B ZieglerDirectorSell31,362$62.00$1,944,444.00View SEC Filing  
5/14/2013John C Md BaldwinDirectorSell1,214$59.41$72,123.74View SEC Filing  
4/11/2013John B ZieglerDirectorSell1,470$58.35$85,774.50View SEC Filing  
1/17/2013Gary M PfeifferDirectorSell10,000$60.00$600,000.00View SEC Filing  
10/3/2012Robert HagemannCFOSell46,667$64.00$2,986,688.00View SEC Filing  
8/7/2012Stephen H RusckowskiCEOBuy5,000$59.34$296,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Quest Diagnostics Incorporated (NYSE:DGX)
Latest Headlines for Quest Diagnostics Incorporated (NYSE:DGX)
DateHeadline logoQuest Diagnostics to Acquire Cleveland HeartLab and Form Strategic Collaboration with Cleveland Clinic - October 18 at 7:19 PM logoQuest Diagnostics Incorporated (DGX) Receives "Hold" Rating from Craig Hallum - October 17 at 10:08 AM logoQuest Diagnostics (DGX) versus The Competition Critical Analysis - October 16 at 10:30 AM logoBrokers Issue Forecasts for Quest Diagnostics Incorporated's Q3 2017 Earnings (DGX) - October 16 at 2:38 AM logoQuest Diagnostics Incorporated (DGX) Research Coverage Started at Wells Fargo & Company - October 15 at 8:31 AM logoHead to Head Analysis: Quest Diagnostics (DGX) vs. Its Peers - October 14 at 6:08 AM logoQuest Diagnostics Incorporated (DGX) Set to Announce Earnings on Thursday - October 12 at 2:12 AM logoGoldman Sachs Group, Inc. (The) Downgrades Quest Diagnostics Incorporated (DGX) to Buy - October 10 at 9:14 AM logoReviewing Quest Diagnostics (DGX) & Laboratory Corporation of America Holdings (LH) - October 7 at 8:38 AM logoQuest Diagnostics (DGX) versus Tenet Healthcare Corporation (THC) Head to Head Review - October 4 at 6:04 PM logoHead-To-Head Contrast: Concord Medical Services Holdings Limited (CCM) versus Quest Diagnostics (DGX) - October 4 at 12:28 PM logoIs Quest Diagnostics (DGX) a Great Stock for Value Investors? - October 3 at 8:23 AM logoQuest Diagnostics Incorporated (DGX) Expected to Post Quarterly Sales of $1.94 Billion - October 3 at 4:42 AM logoQuest Diagnostics to Acquire Shiel Medical Laboratory from Fresenius Medical Care - PR Newswire (press release) - September 30 at 3:49 PM logoQuest Diagnostics To Release Third Quarter 2017 Financial Results On October 19 - September 28 at 5:36 PM logoCredit Suisse Group Cuts Quest Diagnostics Incorporated (DGX) Price Target to $99.00 - September 28 at 12:34 PM logoQuest Diagnostics Incorporated (DGX) Given Consensus Recommendation of "Hold" by Brokerages - September 27 at 2:32 PM logoQuest, LabCorp Are Big 'Losers' Under Medicare Overhaul: Analyst - September 25 at 4:21 PM logoLab services companies’ shares are getting slammed by Medicare reimbursement cuts - September 25 at 4:21 PM logoQuest Diagnostics: Will It Fail The Test? - September 25 at 11:46 AM logoQuest Diagnostics Incorporated (DGX) Receives Market Perform Rating from Raymond James Financial, Inc. - September 25 at 9:38 AM logoQuest Diagnostics Responds to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests - September 22 at 9:58 PM logoHead to Head Comparison: Quest Diagnostics (DGX) and The Competition - September 20 at 8:08 AM logoInteresting DGX Put And Call Options For May 2018 - September 20 at 3:58 AM logoDGX Crosses Below Key Moving Average Level - September 19 at 5:52 PM logoQuest Diagnostics is Oversold - September 18 at 5:49 PM logoMyriad Genetics Presents Favorable riskScore Test Data - September 18 at 5:48 PM logoBrokers Set Expectations for Quest Diagnostics Incorporated's Q1 2019 Earnings (DGX) - September 18 at 8:26 AM logoQuest Diagnostics Inc (DGX) Chairman, President and CEO Stephen H Rusckowski Sold $6. ... - September 14 at 6:42 PM logoQuest Diagnostics Sustainability Efforts Earn Place on DJSI World Index for Fourteenth Consecutive Year - September 14 at 6:42 PM logoQ3 2017 EPS Estimates for Quest Diagnostics Incorporated Decreased by William Blair (DGX) - September 14 at 6:58 AM logo$1.94 Billion in Sales Expected for Quest Diagnostics Incorporated (DGX) This Quarter - September 14 at 2:06 AM logoQuest Diagnostics' (DGX) Buy Rating Reiterated at Canaccord Genuity - September 13 at 8:32 PM logoStephen H. Rusckowski Sells 53,933 Shares of Quest Diagnostics Incorporated (DGX) Stock - September 13 at 7:38 PM logoStephen H. Rusckowski Sells 59,235 Shares of Quest Diagnostics Incorporated (DGX) Stock - September 13 at 7:16 PM logoQuest Diagnostics Incorporated (DGX) Director Daniel Stanzione Sells 40,900 Shares - September 13 at 7:16 PM logoQuest Diagnostics Incorporated (DGX) Expected to Announce Earnings of $1.43 Per Share - September 12 at 10:22 PM logoQuest Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : DGX-US : September 12, 2017 - September 12 at 6:38 PM logoInsider Selling: Quest Diagnostics Incorporated (DGX) Chairman Sells 2,525 Shares of Stock - September 7 at 7:44 PM logoInsider Selling: Quest Diagnostics Incorporated (DGX) Director Sells 3,803 Shares of Stock - September 7 at 7:42 PM logoQuest to offer cholesterol testing without fasting requirement - September 7 at 5:59 PM logoQuest Diagnostics Moves to Convenient Nonfasting Cholesterol Testing with Improved Method for Assessing Heart Disease Risk and Aiding Treatment Decisions - September 7 at 5:59 PM logoMyriad Genetics Boosts myRisk Hereditary Cancer Test Suite - September 6 at 5:52 PM logoHalf of Americans Tested Misuse Their Prescription Medications - September 6 at 5:52 PM logoQuest Diagnostics To Speak At The Morgan Stanley Global Healthcare Conference - September 6 at 5:52 PM logoQuest Diagnostics, Inc. – Value Analysis (NYSE:DGX) : September 6, 2017 - September 6 at 12:28 AM logoQuest Diagnostics Incorporated (DGX) Receives Average Recommendation of "Hold" from Analysts - September 2 at 2:38 PM logoQuest Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : DGX-US : September 1, 2017 - September 1 at 6:12 PM logoWhy Is Quest Diagnostics (DGX) Down 3.9% Since the Last Earnings Report? - Nasdaq - August 30 at 6:56 PM logoMedical Research Stocks on Investors' Radar -- China Cord Blood, VWR Corp., Quest Diagnostics, and LabCorp - August 29 at 6:18 PM



Quest Diagnostics Incorporated (DGX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.